NFKB1 and melanoma: We found that CDK12 inhibition upregulates the expression of AP-1 and NF-κB gene targets (Fig. 4), and show that inhibition of these pathways sensitizes melanoma cells to CDK12 inhibition in vitro (Figs. 5 and 6) and possibly in vivo (Fig. 7).